Search Result

Results for "

P2X2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) HIV (1) Isotope-Labeled Compounds (1) P2X Receptor (23) P2Y Receptor (2) Sodium Channel (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (5) Infection (1) Inflammation/Immunology (9) Neurological Disease (9)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-136254

BzATP triethylammonium salt 4 Publications Verification	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium salt acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium salt is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-19978

RO-3	P2X Receptor	Neurological Disease
RO-3 is a potent, CNS-penetrant, and orally active P2X₃ and *P2X_2/3* antagonist with pIC₅₀s of 5.9 and 7.0 for human homomultimeric P2X₃ and heteromultimeric P2X_2/3 receptors, respectively. RO-3 shows selectivity for P2X₃ and P2X_2/3 over all other functional homomultimeric P2X receptors (IC₅₀ >10 μM at P2X_1,2,4,5,7) .

HY-14483

AF-353 1 Publications Verification Ro-4	P2X Receptor	Cancer
AF-353 (Ro-4) is a potent, selective and orally bioavailable *P2X3/P2X2/3 receptor* antagonist, with a pIC₅₀ of 8.0 for both human and rat P2X3, and with a pIC₅₀ of 7.3 for human P2X2/3 .

HY-16322

Minodronic acid YM-529	P2X Receptor Apoptosis	Cancer
Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic *P2X2/3* receptors involved in pain .

HY-153548

P2X2/3 modulator-1	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X2/3 modulator-1 (Compound 46) is a *P2X2/3* modulator. P2X2/3 modulator-1 can be used in the study of pain, central nervous system disorders and inflammation .

HY-18745

BzATP triethylammonium Benzoylbenzoyl-ATP triethylammonium	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-108673

Ro 0437626	P2X Receptor	Cancer
Ro 0437626 is a selective purinergic (P2X₁) receptor antagonist (IC₅₀ = 3 μM), but shows low affinity for P2X2, P2X3 and P2X2/3 receptors (IC₅₀ > 100 μM) .

HY-14485

Ro-51	P2X Receptor	Neurological Disease
Ro-51 is a potent and selective dual P2X₃/P2X_2/3 antagonist, with IC₅₀ of 2 nM and 5 nM for P2X₃ and P2X_2/3, respectively. Ro-51 can be used for the research for pain .

HY-14483A

AF-353 hydrochloride Ro-4 hydrochloride	P2X Receptor	Cancer
AF-353 hydrochloride is a potent, selective and orally bioavailable *P2X3/P2X2/3 receptor* antagonist, with a pIC₅₀ of 8.0 for both human and rat P2X3, and with a pIC₅₀ of 7.3 for human P2X2/3 .

HY-16322A

Minodronic acid hydrate YM-529 hydrate	P2X Receptor Apoptosis	Cancer
Minodronic acid (YM-529) hydrate is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic *P2X2/3* receptors involved in pain .

HY-137451

Sivopixant S-600918	P2X Receptor	Neurological Disease
Sivopixant (S-600918) is a potent and selective P2X3 receptor antagonist (P2X3 IC₅₀=4.2 nM; P2X2/3 IC₅₀=1100 nM). Sivopixant shows strong analgesic effect .

HY-15568

A-317491 4 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 is a potent, selective and non-nucleotide antagonist of P2X₃ and P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-15568A

A-317491 sodium salt hydrate 4 Publications Verification	P2X Receptor	Neurological Disease Inflammation/Immunology
A-317491 sodium salt hydrate is a potent, selective and non-nucleotide antagonist of P2X₃ and P2X_2/3 receptors, with K_is of 22, 22, 9, and 92 nM for hP2X₃, rP2X₃, hP2X_2/3, and rP2X_2/3, respectively. A-317491 sodium salt hydrate is highly selective (IC50>10 μM) over other P2 receptors and other neurotransmitter receptors, ion channels, and enzymes. A-317491 sodium salt hydrate reduces inflammatory and neuropathic pain by blocking P2X₃ and P2X_2/3 receptor-mediated calcium flux .

HY-16322S

Minodronic acid-d4 YM-529-d₄	Isotope-Labeled Compounds P2X Receptor Apoptosis	Cancer
Minodronic acid-d₄ is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].

HY-134440A

α,β-Methylene-ATP	P2X Receptor	Inflammation/Immunology
α,β-Methylene ATP, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand. α,β-Methylene ATP is a highly selective agonist for P2X1 and P2X3, with practically no activity at P2X2,4-7 .

HY-108652

α,β-Methylene-ATP trisodium	P2X Receptor	Inflammation/Immunology
α,β-Methylene-ATP trisodium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand . α,β-Methylene-ATP trisodium is a highly selective agonist for P2X1 and P2X3, with practically no activity at P2X2,4-7 .

HY-134440

α,β-Methylene-ATP dilithium	P2X Receptor	Inflammation/Immunology
α,β-Methylene ATP dilithium, a phosphonic analog of ATP, is a P2X3 and P2X7 receptor ligand . α,β-Methylene ATP dilithium is a highly selective agonist for P2X1 and P2X3, with practically no activity at P2X2,4-7 .

HY-108676

NF023 hexasodium	P2X Receptor	Neurological Disease
NF023 hexasodium is a selective and competitive P2X₁ receptor antagonist, with IC₅₀ values of 0.21 μM, 28.9 μM, > 50 μM and > 100 μM for human P2X₁, P2X₃, P2X₂, and P2X₄-mediated responses respectively .

HY-D0976

NF279	P2X Receptor HIV	Infection
NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC₅₀ of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC₅₀=1.62 μM), P2X4 (IC₅₀>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env .

HY-112461

NF449	P2X Receptor	Cardiovascular Disease
NF449 is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 is a G_sα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-112461A

NF449 octasodium 1 Publications Verification	P2X Receptor	Cardiovascular Disease
NF449 octasodium is a highly potent P2X₁ receptor antagonist, with IC₅₀s of 0.28, 0.69, and 120 nM for rP2X₁, rP2X₁₊₅, P2X₂₊₃, respectively. NF449 octasodium is a G_sα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to G_sα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to G_s .

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

HY-101308

MRS2179 tetrasodium	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .

HY-135976

P2X3 antagonist 34	P2X Receptor	Neurological Disease Inflammation/Immunology
P2X3 antagonist 34 is a potent, selective and orally active P2X3 homotrimeric receptor antagonist with IC₅₀s of 25 nM, 92 nM and 126 nM for human P2X3, rat P2X3 and guinea pig P2X3 receptors, respectively. P2X3 antagonist 34 is less active against human, rat and guinea pig P2X2/3 heterotrimeric receptors. P2X3 antagonist 34 has strong anti-tussive effect .

HY-101308A

MRS2179 tetrasodium hydrate 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a K_b of 102 nM and a pA₂ of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC₅₀=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .

HY-137606

Uridine adenosine tetraphosphate UP4A	P2X Receptor	Cardiovascular Disease
Uridine adenosine tetraphosphate (UP4A) is an endothelium-derived vasoconstrictor that primarily acts through the P2X1 receptor and possibly through the P2Y2 and P2Y4 receptors. Uridine adenosine tetraphosphate can be used in the study of cardiovascular diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1441A

Mambalgin 1 TFA	Sodium Channel	Neurological Disease
Mambalgin 1 TFA is a selective ASIC1a inhibitor (IC₅₀ values are 192 and 72 nM for human ASIC1a and ASIC1a/1b dimer, respectively). Mambalgin 1 TFA binds to closed/inactive channel. Mambalgin 1 TFA is selective for ASIC1a over ASIC2a, ASIC3, TRPV1, P2X2, 5-HT3, Nav1.8, Cav3.2 and Kv1.2 channels. Mambalgin 1 TFA increases latency of withdrawal response in mouse tail-flick and paw-flick tests.

Cat. No.	Product Name	Chemical Structure

HY-16322S

Minodronic acid-d4
Minodronic acid-d₄ is deuterium labeled Minodronic acid. Minodronic acid (YM-529) is a third-generation bisphosphonate that directly and indirectly prevents proliferation, induces apoptosis, and inhibits metastasis of various types of cancer cells. Minodronic acid (YM-529) is an antagonist of purinergic P2X2/3 receptors involved in pain[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.